Solutions for Healthcare Providers

iStent inject® W

iStent inject® W is indicated for use in conjunction with cataract surgery for the reduction of IOP in adult patients with mild to moderate primary open-angle glaucoma.

Contact Representative

Key Advantages to Using Glaukos Trabecular Micro-Bypass Device During Cataract Surgery Include:

Optimized Outflow

Two multi-directional stents designed to restore natural outflow

Clinically Proven

Significant IOP reduction across a wide range of clinical studies 1 2

Procedural Elegance

Predictability and precision meet the needs of your practice

Proven Safety

Safety profile similar to cataract surgery alone1

All with the Exceptional Customer Support You’ve Come to Expect from Glaukos

Mechanism of Action: Restoring the Natural Outflow Pathway

iStent inject® W creates two patent bypass pathways through the trabecular meshwork—the main source of resistance for aqueous outflow—resulting in multi-directional flow through Schlemm’s canal. And it is one of the smallest medical devices known to be implanted in the human body. Together, these unique advantages are designed to provide exceptional results in a truly micro-invasive approach.

Optimize Outflow

Glaukos trabecular micro-bypass stents are placed two to three clock hours apart. The stents are multi-directional and together, they are designed to deliver access to multiple collector channels and arcs of flow that can span five to six clock hours. The stents may also re-establish flow in previously dormant outflow channels.3

Prioritizing Safety and Outcomes

Putting the primary emphasis on maximizing benefits and minimizing long-term complications, iStent inject® W is designed to support optimal outcomes after cataract surgery and much more:

  • Micro-invasive and astigmatically-neutral
  • Utilizes the conventional outflow pathway
  • Leaves natural anatomy intact, preserving the potential for future treatment options, including drug delivery devices
  • Minimally traumatic to delicate eye tissue and spares conjunctival tissue
  • Reduces risk of hypotony by utilizing the natural episcleral venous pressure
  • Offers postoperative care profile similar to cataract surgery

Exceptional Elegance. Advanced Innovation

The iStent inject® W System is engineered to provide an enhanced surgical experience and ensure confident delivery, for every procedure. With a streamlined injector system and next-generation stent design, featuring a wide flange at its base, iStent inject® W is designed to optimize stent visualization and placement, enhance procedural predictability, and increase peace of mind.

Explore Patient Resources for Glaucoma
Treatment Options

iStent inject® W is indicated for use in adult patients with mild-to-moderate open-angle glaucoma that are undergoing cataract surgery. By taking advantage of this one-time opportunity, you may be able to provide your patients with better IOP control and a reduced dependence on medication.

View Patient Website

Micro Stents. Macro Efficacy.

See the latest clinical data around patient outcomes. iStent inject® W builds on the trabecular micro-bypass technology of iStent inject®, which has demonstrated efficacy across a wide range of clinical studies.

View Clinical Data

Reimbursement Support

Tailor-Made Market Access Solutions

Looking for reimbursement info? The iPath360 program provides strategic and trustworthy market access solutions for all Glaukos procedures and products in glaucoma, corneal health, and retinal disease care.

Reimbursement Info

Resources for Healthcare Professionals

Resources to Help You Make Informed Decisions

As a trusted industry leader – and the corporate founder of MIGS – we have the experience, tools, and training to make integration easy, starting with the resources we make available to you.

View Resources

Contact Us Today to Integrate iStent inject® W Into Your Practice

Complete the form to get started with offering iStent inject® W to your patients. You’ll also receive five posters presented at ARVO 2021 highlighting the efficacy and safety of the iStent platform as compared to other procedures.

Request More Info

Glaukos will use the information you provide on this form to be in touch with you.*
This field is for validation purposes and should be left unchanged.


  • Samuelson TW, Sarkisian SR, Lubeck DM, et al. Prospective, randomized, controlled pivotal trial of an ab interno implanted trabecular micro-bypass in primary open-angle glaucoma and cataract. Ophthalmology. Jun 2019;126(6):811-821.
  • Hengerer FH, Auffarth GU, Riffel C, Conrad-Hengerer I. Prospective, non-randomized, 36-month study of second-generation trabecular micro-bypass stents with phacoemulsification in eyes with various types of glaucoma. Ophthalmol Ther. 2018 Dec;7(2):405-415.
  • Data on file, Glaukos Corporation

iStent inject® W Important Safety Information

Indication for Use

The iStent inject® W Trabecular Micro-Bypass System Model G2-W is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild to moderate primary open-angle glaucoma.


The iStent inject® W is contraindicated in eyes with angle-closure glaucoma, traumatic, malignant, uveitic, or neovascular glaucoma, discernible congenital anomalies of the anterior chamber (AC) angle, retrobulbar tumor, thyroid eye disease, or Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.


Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard.

MRI Information

The iStent inject® W is MR-Conditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details.


The surgeon should monitor the patient postoperatively for proper maintenance of IOP. The safety and effectiveness of the iStent inject® W have not been established as an alternative to the primary treatment of glaucoma with medications, in children, in eyes with significant prior trauma, abnormal anterior segment, chronic inflammation, prior glaucoma surgery (except SLT performed > 90 days preoperative), glaucoma associated with vascular disorders, pseudoexfoliative, pigmentary or other secondary open-angle glaucomas, pseudophakic eyes, phakic eyes without concomitant cataract surgery or with complicated cataract surgery, eyes with medicated IOP > 24 mmHg or unmedicated IOP < 21 mmHg or > 36 mmHg, or for implantation of more or less than two stents.

Adverse Events

Common postoperative adverse events reported in the iStent inject® randomized pivotal trial included stent obstruction (6.2%), intraocular inflammation (5.7% for iStent inject® vs. 4.2% for cataract surgery only), secondary surgical intervention (5.4% vs. 5.0%) and BCVA loss ≥ 2 lines ≥ 3 months (2.6% vs. 4.2%).


Federal law restricts this device to sale by, or on the order of, a physician. Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events.